nChroma Stops First HBV Epigenetic Editing Study

Company nChroma Bio Event Type Clinical study halt and strategic review (previously missed 18 Nov event) Modality Programmable epigenetic silencing Asset CRMA-1001 Target Hepatitis B viral transcription Disease Area Chronic hepatitis B Summary nChroma disclosed November 18 that it stopped enrollment and dosing in its…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *